1
|
Papp D, Kovács T, Billes V, Varga M, Tarnóci A, Hackler L, Puskás LG, Liliom H, Tárnok K, Schlett K, Borsy A, Pádár Z, Kovács AL, Hegedűs K, Juhász G, Komlós M, Erdős A, Gulyás B, Vellai T. AUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects. Autophagy 2016; 12:273-86. [PMID: 26312549 DOI: 10.1080/15548627.2015.1082023] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Autophagy is a major molecular mechanism that eliminates cellular damage in eukaryotic organisms. Basal levels of autophagy are required for maintaining cellular homeostasis and functioning. Defects in the autophagic process are implicated in the development of various age-dependent pathologies including cancer and neurodegenerative diseases, as well as in accelerated aging. Genetic activation of autophagy has been shown to retard the accumulation of damaged cytoplasmic constituents, delay the incidence of age-dependent diseases, and extend life span in genetic models. This implies that autophagy serves as a therapeutic target in treating such pathologies. Although several autophagy-inducing chemical agents have been identified, the majority of them operate upstream of the core autophagic process, thereby exerting undesired side effects. Here, we screened a small-molecule library for specific inhibitors of MTMR14, a myotubularin-related phosphatase antagonizing the formation of autophagic membrane structures, and isolated AUTEN-67 (autophagy enhancer-67) that significantly increases autophagic flux in cell lines and in vivo models. AUTEN-67 promotes longevity and protects neurons from undergoing stress-induced cell death. It also restores nesting behavior in a murine model of Alzheimer disease, without apparent side effects. Thus, AUTEN-67 is a potent drug candidate for treating autophagy-related diseases.
Collapse
Affiliation(s)
- Diána Papp
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary
| | - Tibor Kovács
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary.,b Department of Genetics , Eötvös Loránd University , Budapest , Hungary
| | - Viktor Billes
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary.,b Department of Genetics , Eötvös Loránd University , Budapest , Hungary
| | - Máté Varga
- b Department of Genetics , Eötvös Loránd University , Budapest , Hungary
| | - Anna Tarnóci
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary.,b Department of Genetics , Eötvös Loránd University , Budapest , Hungary
| | | | - László G Puskás
- c Avidin Ltd. , Szeged , Hungary.,d Laboratory of Functional Genomics, Institute of Genetics, Biological Research Center , Szeged , Hungary
| | - Hanna Liliom
- e Department of Physiology and Neurobiology , Eötvös Loránd University , Budapest , Hungary
| | - Krisztián Tárnok
- e Department of Physiology and Neurobiology , Eötvös Loránd University , Budapest , Hungary
| | - Katalin Schlett
- e Department of Physiology and Neurobiology , Eötvös Loránd University , Budapest , Hungary.,f MTA-ELTE NAP B Neuronal Cell Biology Research Group, Eötvös Loránd University , Budapest , Hungary
| | - Adrienn Borsy
- g Institute of Enzymology, Research Center for Natural Sciences , Budapest , Hungary
| | - Zsolt Pádár
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary
| | - Attila L Kovács
- h Department of Anatomy , Cell and Developmental Biology, Eötvös Loránd University , Budapest , Hungary
| | - Krisztina Hegedűs
- h Department of Anatomy , Cell and Developmental Biology, Eötvös Loránd University , Budapest , Hungary
| | - Gábor Juhász
- h Department of Anatomy , Cell and Developmental Biology, Eötvös Loránd University , Budapest , Hungary
| | - Marcell Komlós
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary
| | - Attila Erdős
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary
| | - Balázs Gulyás
- i Karolinska Institute , Department of Clinical Neuroscience , Stockholm , Sweden.,j Imperial College-NTU, Lee Kong Chian School of Medicine, Nanyang Technological University , Singapore.,k Imperial College London , Department of Medicine, Division of Brain Sciences , London , UK
| | - Tibor Vellai
- a Velgene Biotechnology Research Ltd. , Szeged , Hungary.,b Department of Genetics , Eötvös Loránd University , Budapest , Hungary
| |
Collapse
|
2
|
Helal KY, Maciejewski M, Gregori-Puigjané E, Glick M, Wassermann AM. Public Domain HTS Fingerprints: Design and Evaluation of Compound Bioactivity Profiles from PubChem's Bioassay Repository. J Chem Inf Model 2016; 56:390-8. [PMID: 26898267 DOI: 10.1021/acs.jcim.5b00498] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Molecular profiling efforts aim at characterizing the biological actions of small molecules by screening them in hundreds of different biochemical and/or cell-based assays. Together, these assays yield a rich data landscape of target-based and phenotypic effects of the tested compounds. However, submitting an entire compound library to a molecular profiling panel can easily become cost-prohibitive. Here, we make use of historical screening assays to create comprehensive bioactivity profiles for more than 300 000 small molecules. These bioactivity profiles, termed PubChem high-throughput screening fingerprints (PubChem HTSFPs), report small molecule activities in 243 different PubChem bioassays. Although the assays originate from originally independently pursued drug or probe discovery projects, we demonstrate their value as molecular signatures when used in combination. We use these PubChem HTSFPs as molecular descriptors in hit expansion experiments for 33 different targets and phenotypes, showing that, on average, they lead to 27 times as many hits in a set of 1000 chosen molecules as a random screening subset of the same size (average ROC score: 0.82). Moreover, we demonstrate that PubChem HTSFPs retrieve hits that are structurally diverse and distinct from active compounds retrieved by chemical similarity-based hit expansion methods. PubChem HTSFPs are made freely available for the chemical biology research community.
Collapse
Affiliation(s)
- Kazi Yasin Helal
- Novartis Institutes for Biomedical Research Inc. , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Mateusz Maciejewski
- Pfizer Inc. , 610 Main Street, Cambridge, Massachusetts 02139, United States
| | - Elisabet Gregori-Puigjané
- Novartis Institutes for Biomedical Research Inc. , 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, United States
| | - Meir Glick
- Merck Research Laboratories , Boston, Massachusetts 02115, United States
| | - Anne Mai Wassermann
- Pfizer Inc. , 610 Main Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
3
|
Combination of small molecule microarray and confocal microscopy techniques for live cell staining fluorescent dye discovery. Molecules 2013; 18:9999-10013. [PMID: 23966084 PMCID: PMC6270374 DOI: 10.3390/molecules18089999] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Revised: 08/13/2013] [Accepted: 08/14/2013] [Indexed: 01/25/2023] Open
Abstract
Discovering new fluorochromes is significantly advanced by high-throughput screening (HTS) methods. In the present study a combination of small molecule microarray (SMM) prescreening and confocal laser scanning microscopy (CLSM) was developed in order to discover novel cell staining fluorescent dyes. Compounds with high native fluorescence were selected from a 14,585-member library and further tested on living cells under the microscope. Eleven compartment-specific, cell-permeable (or plasma membrane-targeted) fluorochromes were identified. Their cytotoxicity was tested and found that between 1–10 micromolar range, they were non-toxic even during long-term incubations.
Collapse
|
5
|
Proteomic methods for drug target discovery. Curr Opin Chem Biol 2008; 12:46-54. [PMID: 18282485 DOI: 10.1016/j.cbpa.2008.01.022] [Citation(s) in RCA: 88] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2007] [Accepted: 01/15/2008] [Indexed: 11/22/2022]
Abstract
The field of drug target discovery is currently very popular with a great potential for advancing biomedical research and chemical genomics. Innovative strategies have been developed to aid the process of target identification, either by elucidating the primary mechanism-of-action of a drug, by understanding side effects involving unanticipated 'off-target' interactions, or by finding new potential therapeutic value for an established drug. Several promising proteomic methods have been introduced for directly isolating and identifying the protein targets of interest that are bound by active small molecules or for visualizing enzyme activities affected by drug treatment. Significant progress has been made in this rapidly advancing field, speeding the clinical validation of drug candidates and the discovery of the novel targets for lead compounds developed using cell-based phenotypic screens. Using these proteomic methods, further insight into drug activity and toxicity can be ascertained.
Collapse
|